Optimizing First-Line and Sequential Therapy in Advanced NSCLC

Opinion
Video

Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.

Video content above is prompted by the following:

  • What role do biomarkers like PD-L1 play in determining first-line therapy options for advanced NSCLC, and how does level of expression impact initial drug choice?
  • What other patient characteristics influence initial treatment choices in advanced NSCLC, and how do they support using PD-1s as first-line options?
  • Following disease progression on initial therapy, how frequently are PD-1 inhibitors used alone or in combination for subsequent lines of treatment?

Recent Videos
2 experts in this video
1 expert in this video
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.